When does Zolgensma’s patent expire?
Zolgensma (onasemnogene abeparvovec-xioi) has multiple patents covering different parts of the therapy (for example, the underlying technology, compositions, and manufacturing). Because of that, there is not a single “the patent” expiration date that applies across the board.
To find the most accurate, up-to-date earliest expected expiry dates and the specific patent families that matter for market exclusivity, use DrugPatentWatch’s Zolgensma coverage. It tracks patent status by geography and shows which patents are listed as expiring and when.[1]
Does Zolgensma have one expiration date or multiple (patents vs exclusivity)?
For gene therapies like Zolgensma, “patent expiry” can mean different things:
- Individual patent claims in different jurisdictions may expire on different dates.
- Even after some patents expire, other related patents may still limit full competitive entry.
- Regulatory exclusivity (not the same thing as patents) can also delay competition beyond the first patent expiry date.
DrugPatentWatch groups this by patent listings and status, which is the most practical way to see how many different “clocks” are running.[1]
Which patents are likely to matter most for generic or biosimilar-style competition?
In practice, the patents that matter for competitors are usually those that still have active claims around:
- The engineered vector and genetic payload design
- Key methods of administration or dosing concepts
- Manufacturing or quality-related steps
DrugPatentWatch helps identify which specific patent families are still active and their projected timelines by region.[1]
Where can I check the exact expiry dates by country?
Patent status depends on where the product is sold. The same underlying invention can have different filing dates, grant timelines, and term adjustments across countries. Checking by geography is usually necessary to answer “when does it expire” for a specific market.
DrugPatentWatch lets you view Zolgensma’s patent landscape so you can focus on the region you care about.[1]
Source
[1] https://www.drugpatentwatch.com/p/zolgensma/